These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 34459681)

  • 1. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
    Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L
    Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
    Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
    Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
    Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S
    J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
    Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
    J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
    Gagelmann N; Ayuk F; Atanackovic D; Kröger N
    Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials.
    Hu D; Chen L; Yan D; Dong W; Chen M; Niu S; Wang S; Zhang J; Nie X; Fang Y
    Front Pharmacol; 2023; 14():1149138. PubMed ID: 37408760
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
    Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J
    Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
    Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
    N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
    Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
    Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
    Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
    Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.
    Zhang M; Zhou L; Zhao H; Zhang Y; Wei G; Hong R; Wu W; Xu H; Wang L; Ni F; Cui J; Peng S; Huang CH; Chang AH; Hu Y; Huang H
    Clin Cancer Res; 2021 Dec; 27(23):6384-6392. PubMed ID: 34548316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
    Xu J; Wang BY; Yu SH; Chen SJ; Yang SS; Liu R; Chen LJ; Hou J; Chen Z; Zhao WH; He AL; Mi JQ; Chen SJ
    J Hematol Oncol; 2024 Apr; 17(1):23. PubMed ID: 38659046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
    Xu H; Guan C; Xu P; Zhou D; Xu Y; Chen B; Bai H
    Front Oncol; 2024; 14():1355643. PubMed ID: 38651157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease.
    Li W; Liu M; Yuan T; Yan L; Cui R; Deng Q
    Hematol Oncol; 2022 Apr; 40(2):223-232. PubMed ID: 34942032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis.
    Akhtar OS; Sheeba BA; Azad F; Alessi L; Hansen D; Alsina M; Baz R; Shain K; Grajales Cruz A; Castaneda Puglianini O; Liu H; Blue B; Nishihori T; Al Jumayli M; Extermann M; Locke FL; Mhaskar R; Freeman CL
    J Geriatr Oncol; 2024 Mar; 15(2):101628. PubMed ID: 37723045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
    Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
    Front Immunol; 2021; 12():609421. PubMed ID: 33767695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.